Medical/Pharmaceuticals
GEM and Senhwa Biosciences have formally executed a Share Purchase Agreement for up to NT$500 million
TAIPEI and SAN DIEGO, July 14, 2026 /PRNewswire/ -- GEM Global Yield LLC SCS ("GEM") has executed a Share Purchase Agreement (the "SPA") with the existing shareholders of Taiwan-listed Senhwa Biosciences Inc. (TPEx: 6492), under which GEM has committed up to NT$500 million (approximately US$15.5 ...
2026-07-15 09:09
3459
Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore a next-generation drug innovation model CAMBRIDGE, Mass. and TAIPEI, July 14, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-s...
2026-07-15 08:00
3016
ACROBiosystems Obtains PMDA Material Suitability Confirmation for GMP-grade IL-15, Ensuring Reliable Quality and Strengthening the Biopharmaceutical Approval Process
NEWARK, Del., July 14, 2026 /PRNewswire/ -- Recently, ACROBiosystems has officially received the "Material Suitability Confirmation for Regenerative Medicine Products" (Certificate No.: 薬機審長発第47号) from the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for its GMP-grade Human IL-15 pr...
2026-07-15 00:00
3900
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
* BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor developed from a hit identified via HitGen's DEL technology platform, has advanced into a Phase 2 proof-of-concept trial for cardiovascular risk reduction. * The QUELL-CV trial is designe...
2026-07-14 21:30
3976
Rayence Launches 'SHINE,' a Next-Generation X-ray Image Processing Technology for Low Dose Imaging
- Development of next-generation denoising image processing technology 'SHINE' completed; full-scale commercialization now underway - Development of 'Dynamic SHINE,' optimized for real-time C-arm fluoroscopy, also completed - SHINE is expected to help global X-ray equipment manufacturers acceler...
2026-07-14 21:00
2905
Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer
HONG KONG, July 14, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study evaluating a cadonilimab-based combination regimen for the pe...
2026-07-14 16:18
2694
Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities
SAN DIEGO, July 13, 2026 /PRNewswire/ -- Ahead of the BIO International Convention, BIOSeedin Summer Innovation Partnering Summit was successfully held at Wyndham San Diego Bayside, California. Hosted by bioSeedin, the summit's discussion topics were about early-stage innovation assets, late-stag...
2026-07-14 00:00
3528
HKEY-AI-NAM-Bridge™ 1.0: HKeyBio Connects AI, NAMs and In Vivo Evidence
HKEY-AI-NAM-Bridge™ 1.0 connects AI predictions, new approach methodologies and in vivo evidence for more targeted preclinical study design BOSTON and SUZHOU, China, July 13, 2026 /PRNewswire/ -- HKeyBio has establishedHKEY-AI-NAM-Bridge™ 1.0, its AI and New Approach Methodologies (NAMs) In Vivo...
2026-07-13 21:16
2834
Delonix Bioworks Announces First Participant Dosed in Phase 1 Clinical Trial of Next-Generation MenB OMV Vaccine DX-104 in China
SHANGHAI, July 13, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, today announced that the first participant has been dosed in its Phase 1 clinical trial of DX-104 in China. DX-104 is an innovative Group B menin...
2026-07-13 20:00
2872
Advancing Low-Carbon Manufacturing and Global Sustainability Commitments
Report highlights clean energy, innovation and ESG recognition
ZIBO, China, July 13, 2026 /PRNewswire/ -- INTCO Medical
2026-07-13 17:19
3230
Leads Biolabs Announces Multiple Studies Selected for ESMO 2026, Highlighting the Growing Global Competitiveness of Its Core Pipeline
NANJING, China, July 13, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that six of its latest research studies have been accepted for presentation at the 2026 European Society for Medical Oncology (ESMO) Annual Congres...
2026-07-13 16:56
2784
Boostimmune Secures Japanese Patent for Sequence-Independent TCTP Antibody Technology Targeting MDSC Accumulation
* Japanese patent granted for technology that inhibits TCTP released from dead tumor cells using antibodies to suppress the accumulation of MDSCs in the tumor microenvironment * Granted claims are not expressly limited to specific antibody CDRs or amino acid sequences, but are defined by func...
2026-07-13 16:53
2456
Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
SHANGHAI, July 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI),and China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical ...
2026-07-13 08:30
2782
Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC
NANJING, China, July 10, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license application (BLA) for Opamtistomig (LBL-024, a PD-L1/4-1BB bispecific antibody) as monotherapy for the treatment of adva...
2026-07-10 16:53
4045
Professor Gang Shen's Orthodontic Team Publishes Third Consecutive Paper in the Journal of Aligner Orthodontics
SHANGHAI, July 8, 2026 /PRNewswire/ -- Professor Gang Shen, Chief GS R&D Scientist of Smartee Denti-Technology and Chief Orthodontist at Taikang Dental, together with his orthodontic team, has published a new researcharticle titled " Pathological Mandibular Retrusion: Causality and Orthodontic Int...
2026-07-09 17:55
3417
InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation
NANJING, China, July 9, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selective...
2026-07-09 17:28
3578
WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
SHIJIAZHUANG, China, July 9, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance manufacturing facility located in Hebei has successfully passed the Pre-License Inspection (PL...
2026-07-09 15:31
3474
Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine
HANGZHOU, China, July 8, 2026 /PRNewswire/ -- On July 8, the study of Betta's ensartinib as postoperative adjuvant therapy for patients with stage IB–IIIB (T3N2M0) ALK-positive non-small cell lung cancer (NSCLC), known as the ELEVATE study,was published online in full in The New England Journal o...
2026-07-09 10:16
3212
HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership
Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist InxMed. TAIPEI and SHANGHAI and SAN FRANCISCO, July 8, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827) is taking another step to broaden th...
2026-07-09 09:13
2798
Insilico Medicine Releases Positive Profit Alert for the First Half of 2026
CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive profit alert for the six months ended June 30, 2026 ("First Half of 2026"). The s...
2026-07-09 08:30
2884
Week's Top Stories
Most Reposted
DBS crowned Southeast Asia's most valuable brand in Kantar BrandZ 2026 ranking
[Picked up by 308 media titles]
2026-07-15 12:00
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent
[Picked up by 305 media titles]
2026-07-16 10:00
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
[Picked up by 295 media titles]
2026-07-20 15:00
Singapore Tourism Board and Traveloka Renew Partnership to Welcome More Southeast Asian and Australian Travellers to Singapore
[Picked up by 291 media titles]
2026-07-17 18:18
Klook signs an expanded two-year partnership with Korea Tourism Organization
[Picked up by 288 media titles]
2026-07-16 17:49
Most Read
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent
2026-07-16 10:00
14815
DBS crowned Southeast Asia's most valuable brand in Kantar BrandZ 2026 ranking
2026-07-15 12:00
11530
Klook signs an expanded two-year partnership with Korea Tourism Organization
2026-07-16 17:49
10467